Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Key Event: On June 11, 2026, Adial completed the acquisition of Azora Therapeutics, Inc. ("Azora"). This transaction shifted the Company's strategic focus from its legacy program (AD04 for Alcohol Use Disorder) to Azora's lead candidate, AT177, a colon-targeted AhR agonist for Ulcerative Colitis. The acquisition was accounted for as the consolidation of a Variable Interest Entity (VIE).
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(54,012) | $(4,188) |
| Loss Per Share (Basic & Diluted) | $(17.97) | $(12.19) |
| Cash and Cash Equivalents (End of Period) | $28,712 | $5,915 |
| Net Cash Used in Operating Activities | $(7,975) | $(3,335) |
| Net Cash Provided by Financing Activities | $25,524 | $5,349 |
| Total Assets | $29,089 | $6,674 |
| Total Liabilities | $28,933 | $1,397 |
| Stockholders' Deficit | $(38,377) | $5,277 |
Note: The Company reported no revenue for either period. The significant increase in liabilities is primarily due to the recognition of a $23.8 million milestone warrant rights liability and $38.5 million in Series A Convertible Preferred Stock classified as temporary equity.
Material Changes vs. Prior Period
- Acquired In-Process R&D (IPR&D): The Company recognized a non-cash expense of $46.2 million related to the acquisition of Azora's IPR&D assets, which had no alternative future use. This was the primary driver of the increased operating loss.
- Operating Expenses: Total operating expenses surged to $54.0 million (vs. $4.2 million in the prior year), driven by the $46.2 million IPR&D charge and increased General and Administrative (G&A) expenses ($7.0 million vs. $2.7 million) due to merger-related costs and severance.
- Financing Activity: The Company raised approximately $26.8 million in gross proceeds through a private placement of pre-funded warrants (PIPE) and exchanged $5.5 million of Azora's convertible notes for pre-funded warrants. This resulted in a net cash increase of $22.8 million for the period.
- Equity Structure: Issued 12,930.617 shares of Series A Convertible Preferred Stock (convertible into ~12.9 million common shares) to former Azora shareholders. Issued ~11.8 million pre-funded warrants to PIPE investors.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern. Current cash ($28.7 million) is not expected to fund operations for the next 12 months. Additional financing is required to complete IND-enabling studies and Phase 1 trials for AT177.
- Outlook: The Company plans to file an Investigational New Drug (IND) application for AT177 in Q2 2027, with Phase 1a trials starting in H2 2027 and a proof-of-concept readout anticipated in H1 2028.
- Contingent Funding: The Company has the option to raise an additional ~$32.4 million through "Milestone Warrants" if specific clinical or stock price milestones are met. However, investors are not obligated to purchase these warrants.
- Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the accounting of the complex Merger and Financing transactions. Disclosure controls were deemed ineffective as of June 30, 2026.
- Nasdaq Compliance: The Company's stockholders' equity ($38.4 million deficit) does not meet Nasdaq continued listing requirements. The Company expects to regain compliance upon stockholder approval of the conversion of Series A Preferred Stock, but delisting risks remain.
- Cash Settlement Risk: If stockholder approval for the conversion of Series A Preferred Stock is not obtained by December 11, 2026, holders may demand cash settlement, which could deplete available cash resources.
Investor Verification Checklist
- Capital Sufficiency: Verify the timeline and certainty of raising additional capital beyond the current $28.7 million cash balance to fund the 2027-2028 development plan.
- Stockholder Approval: Monitor the status of the upcoming 2026 Annual Meeting to approve the conversion of Series A Preferred Stock and the exercise of warrants, which is critical for avoiding cash settlement obligations and maintaining Nasdaq listing.
- Internal Controls: Review the remediation plan for the identified material weakness in financial reporting controls.
- Milestone Warrant Exercise: Assess the likelihood of PIPE investors exercising the optional Milestone Warrants to provide the projected $32.4 million in future funding.
- AT177 Development: Track progress on IND-enabling studies and the planned Q2 2027 IND filing, as the Company's value is now concentrated in this single asset.